{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+T+Cell+Lymphoma+%28CTCL%29&page=2",
    "query": {
      "condition": "Cutaneous T Cell Lymphoma (CTCL)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+T+Cell+Lymphoma+%28CTCL%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T02:50:57.776Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01678443",
      "title": "Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Hairy Cell Leukemia",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "T-cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "indium In 111 anti-CD45 monoclonal antibody BC8",
          "type": "BIOLOGICAL"
        },
        {
          "name": "yttrium Y 90 anti-CD45 monoclonal antibody BC8",
          "type": "RADIATION"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "1999-09-01",
      "completion_date": "2018-09-27",
      "has_results": true,
      "last_update_posted_date": "2021-04-02",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01678443"
    },
    {
      "nct_id": "NCT00019513",
      "title": "Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Liver Cancer",
        "Lung Cancer",
        "Lymphoma",
        "Pancreatic Cancer",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "1998-08",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019513"
    },
    {
      "nct_id": "NCT03409432",
      "title": "Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphomatoid Papulosis",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "John Reneau",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2018-03-16",
      "completion_date": "2025-07-16",
      "has_results": false,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409432"
    },
    {
      "nct_id": "NCT00047164",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 89,
      "start_date": "2002-09",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2016-09-26",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047164"
    },
    {
      "nct_id": "NCT03240211",
      "title": "Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PTCL",
        "CTCL"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pralatrexate",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 37,
      "start_date": "2022-02-02",
      "completion_date": "2026-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03240211"
    },
    {
      "nct_id": "NCT04712864",
      "title": "Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-Cell Lymphoma",
        "Peripheral T-Cell Lymphoma Refractory",
        "Cutaneous T-Cell Lymphoma Refractory",
        "Cutaneous T-Cell Lymphoma Recurrent",
        "Peripheral T-Cell Lymphoma Recurrent"
      ],
      "interventions": [
        {
          "name": "LB1901",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Legend Biotech USA Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-09-13",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 4,
      "location_summary": "Rochester, Minnesota • Houston, Texas • Seattle, Washington + 1 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04712864"
    },
    {
      "nct_id": "NCT00274651",
      "title": "A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous T-Cell Lymphoma",
        "Peripheral T-Cell Lymphoma",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "belinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valerio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2006-01",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2015-07-28",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 8,
      "location_summary": "Stanford, California • New Haven, Connecticut • Lenexa, Kansas + 4 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274651"
    },
    {
      "nct_id": "NCT06712810",
      "title": "Q702 for the Treatment of Patients With Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm",
        "Histiocytic Sarcoma",
        "Malignant Histiocytosis",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Follicular Lymphoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Myelodysplastic Syndrome",
        "Recurrent Myelofibrosis",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent Waldenstrom Macroglobulinemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Erdheim-Chester Disease",
        "Refractory Follicular Lymphoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Myelodysplastic Syndrome",
        "Refractory Myelofibrosis",
        "Refractory Small Lymphocytic Lymphoma",
        "Refractory Waldenstrom Macroglobulinemia",
        "Rosai-Dorfman-Destombes Disease",
        "Primary Central Nervous System Lymphoma",
        "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Recurrent Erdheim-Chester Disease",
        "Recurrent Fibroblastic Reticular Cell Sarcoma",
        "Recurrent Histiocytic Sarcoma",
        "Recurrent Interdigitating Dendritic Cell Sarcoma",
        "Recurrent Rosai-Dorfman-Destombes Disease",
        "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Refractory Fibroblastic Reticular Cell Sarcoma",
        "Refractory Histiocytic Sarcoma",
        "Refractory Interdigitating Dendritic Cell Sarcoma",
        "Refractory Rosai-Dorfman-Destombes Disease"
      ],
      "interventions": [
        {
          "name": "Axl/Mer/CSF1R Inhibitor Q702",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2025-08-27",
      "completion_date": "2030-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712810"
    },
    {
      "nct_id": "NCT00589381",
      "title": "Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fenretinide lipid matrix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-08",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589381"
    },
    {
      "nct_id": "NCT00324324",
      "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Infection",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "moxifloxacin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 240,
      "start_date": "2006-05",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-06-26T02:50:57.776Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324324"
    }
  ]
}